Cargando…
Association of QT interval-prolonging drugs with clinical trial eligibility in patients with advanced cancer
INTRODUCTION: Drug-induced prolongation of the heart rate-corrected QT interval (QTc) is associated with increased risk for the potentially fatal arrhythmia torsades de pointes. Due to arrhythmia risk, clinical trials with cancer therapeutics often exclude patients based on thresholds for QTc prolon...
Autores principales: | Rowe, Elizabeth J., Shugg, Tyler, Ly, Reynold C., Philips, Santosh, Rosenman, Marc B., Callaghan, John T., Radovich, Milan, Overholser, Brian R., Schneider, Bryan P., Tisdale, James E., Skaar, Todd C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9798408/ https://www.ncbi.nlm.nih.gov/pubmed/36588548 http://dx.doi.org/10.3389/fcvm.2022.894623 |
Ejemplares similares
-
Life-Threatening Docetaxel Toxicity in a Patient With Reduced-Function CYP3A Variants: A Case Report
por: Powell, Nicholas R., et al.
Publicado: (2022) -
QT Prolongation in Cancer Patients
por: Kim, Peter, et al.
Publicado: (2021) -
QT Interval Prolongation Is a Novel Predictor of 1-Year Mortality in Patients With COVID-19 Infection
por: Banai, Ariel, et al.
Publicado: (2022) -
Effect of QT interval-prolonging drugs taken in pregnancy on the neonatal QT interval
por: Michel, Holger, et al.
Publicado: (2023) -
Beyond a prolonged QT interval
por: Bitar, Zouheir Ibrahim, et al.
Publicado: (2013)